speaker

Stephanie Weiss

MD

It has been her long-term ambition to treat patients suffering from cancer. Even before medical school, she had been a member of a cancer research team at Mount Sinai Hospital in New York City where she had the opportunity to contribute to several scientific publications on the subject of breast cancer. As a medical student at St. George’s University School of Medicine, she pursued this interest by taking a number of electives in the field. She chose to specialize in radiation oncology because it affords her the opportunity to interact directly with patients on a daily basis and to participate in clinical research programs designed to explore new treatment modalities.

After her internship at Upstate Medical University in NY, she trained in radiation oncology at Johns Hopkins Hospital and obtained broad experience in all subspecialty areas of radiation oncology. In her final year, she was appointed as Chief Resident.

Following completion of her residency, she received an appointment as an attending physician at Brigham and Women’s Hospital/Dana Farber Cancer Institute and was on faculty at Harvard Medical School. She specialized in the treatment of brain tumors and in 2007 was appointed Chief of Adult Tumors of the Central Nervous System Tumors and Radiosurgery.

She has extensive experience with several technologies used in treating cancer patients including stereotactic radiosurgery, hypo-fractionation, volumetric arc therapy, and intensity-modulated radiotherapy. Her research activities primarily involved seeking to improve outcomes for patients, and have been presented at national and international meetings, won grants, and been selected for plenary sessions. (see publications).

In 2012 she joined the Department of Radiation Oncology at Fox Chase Cancer Center as an attending physician and Associate Professor. She will continue to be involved in the treatment of patients with cancer and also contribute to the development of the brain tumor service. Her clinical research activities will, as in the past, focus on developing and assessing new treatment protocols that will provide better outcomes for patients.